Involvement of hydrogen peroxide in histamine-induced modulation of WM35 human malignant melanoma cell proliferation

Free Radical Biology and Medicine

Volumn 46, Issue 11, 2009, Pages 1510-1515

  Medina, Vanina A ^a,b   Massari, Noelia A ^a   Cricco, Graciela P ^a   Martín, Gabriela A ^a,b   Bergoc, Rosa M ^a,b   Rivera, Elena S ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Antioxidant enzymes; Cell proliferation; Free radicals; Histamine; Melanoma; Reactive oxygen species; Senescence

Indexed keywords

CATALASE; HISTAMINE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL;

CATALASE; CELL AGING; CELL PROLIFERATION; ENZYME ACTIVATION; HISTAMINE; HUMANS; HYDROGEN PEROXIDE; MELANOMA; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 67349088734     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.03.003     Document Type: Article

References (37)

1. Markovic S.N., Erickson L.A., Rao R.D., Weenig R.H., Pockaj B.A., Bardia A., Vachon C.M., Schild S.E., McWilliams R.R., Hand J.L., Laman S.D., Kottschade L.A., Maples W.J., Pittelkow M.R., Pulido J.S., Cameron J.D., and Creagan E.T. Malignant melanoma in the 21st century. Part 1. Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc. 82 (2007) 364-380
2. Gray-Schopfer V., Wellbrock C., and Marais R. Melanoma biology and new targeted therapy. Nature 445 (2007) 851-857
3. Agarwala S.S., Hellstrand K., Gehlsen K., and Naredi P. Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol. Immunother. 53 (2004) 840-841
4. Galmarini C.M. Histamine dihydrochloride (subcutaneous) Maxim. Curr. Opin. Invest. Drugs 5 (2004) 1298-1310
5. Mitchell M.S. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. 3 (2003) 1051-1059
6. Molnár E.L., Hegyesi H., Tóth S., Darvas Z., Laszló V., Szalai C., and Falus A. Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. Semin. Cancer Biol. 10 (2000) 25-28
7. Molnár E.L., Hegyesi H., Tóth S., and Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12 (2000) 547-554
8. Haak-Frendscho M., Darvas A., Hegyesi H., Karpati S., Hoffman R., Laszló V., Bencsath M., Szalai C., Fürész J., Timár J., Bata-Csörgo Z., Szabad G., Pivarcsi A., Pállinger É., Kemény L., Horváth A., Dovozy A., and Falus A. Histidine decarboxylase expression in human melanoma. J. Invest. Dermatol. 115 (2000) 345-352
9. Darvas Z., Sakurai E., Schwelberger H.G., Hegyesi H., Rivera E., Othsu H., Watanabe T., Pállinger E., and Falus A. Autonomous histamine metabolism in human melanoma cells. Melanoma Res. 13 (2003) 239-246
10. Hegyesi H., Horváth B., Pállinger E., Pós Z., Mólnar E.L., and Falus A. Histamine elevates the expression of Ets-1, a protooncogene in human melanoma cell lines through H2 receptor. FEBS Lett. 579 (2005) 2469-2475
11. 2+-mobilizing H1 receptors. J. Cell Biol. 110 (1990) 1211-1215
12. Hegyesi H., Somlai B., Varga V.L., Toth G., Kovacs P., Mólnar E.L., Laszlo V., Karpati S., Rivera E., Falus A., and Darvas Z. Suppression of melanoma cell proliferation by histidine decarboxylase specific antisense oligonucleotides. J. Invest. Dermatol. 117 (2001) 151-153
13. Molnár E.L., Cricco G., Martin G., Darvas Z., Hegyesi H., Fitzsimons C., Bergoc R., Falus A., and Rivera E. Histamine as a potential autocrine regulator of melanoma. Inflammation Res. 50 (2001) S102-S103
14. Molnár E.L., Hegyesi H., Pállinger E., Kovács P., Tóth S., Fitzsimons C., Cricco G., Martin G., Bergoc R., Darvas Z., Rivera E.S., and Falus A. Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur. J. Clin. Invest. 32 (2002) 743-749
15. Reynolds J.L., Akhter J., and Morris D.L. In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. Melanoma Res. 6 (1996) 95-99
16. Pós Z., Hegyesi H., and Rivera E.S. Histamine and cell proliferation. In: Falus A. (Ed). Histamine: Biology and Medical Aspects (2004), SpringMed Publ., Budapest 199-217
17. Medina V., Cricco G., Nuñez M., Martín G., Mohamad N., Correa-Fiz F., Sanchez-Jimenez F., Bergoc R., and Rivera E. Histamine-mediated signaling processes in human malignant mammary cells. Cancer Biol. Ther. 5 (2006) 1462-1471
18. Pani G., Bedogni B., Anzevino R., Colavitti R., Palazzotti B., Borello S., and Galeotti T. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p-53-deficient cells. Cancer Res. 60 (2000) 4654-4660
19. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82 (2002) 47-95
20. Karihtala P., and Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115 (2007) 81-103
21. Dimri G.P., Lee X., Basile G., Acosta M., Scout G., Roskelley C., Medrano E., Linskens M., Rubeli I., Pereira-Smith O., and Peacocke M. A biomarker that identifies senescent human cells in culture and aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 9363-9367
22. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
23. Policastro L., Molinari B., Larcher F., Blanco P., Podhajcer O.L., Costa C.S., Rojas P., and Durán H. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol. Carcinog. 39 (2004) 103-113
24. Flohé L., and Gunzler W.A. Assays of glutathione peroxidase. Methods Enzymol. 105 (1984) 114-121
25. Kim R., Emi M., and Tanabe K. Role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol. Ther. 52 (2006) 1424-1429
26. Lee A.C., Fenster B.E., Ito H., Takeda K., Bae N.S., Hirai T., Yu Z.X., Ferrans V.J., Howard B.H., and Finkel T. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 274 (1999) 7936-7940
27. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res. 63 (2003) 2705-2715
28. Lu T., and Finkel T. Free radicals and senescence. Exp. Cell Res. 314 (2008) 1918-1922
29. López-Lázaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 252 (2007) 1-8
30. Adler V., Yin Z., Tew K.D., and Ronai Z. Role of redox potential and reactive oxygen species in stress signalling. Oncogene 18 (1999) 6104-6111
31. Li S., Yan T., Yang J.Q., Oberley T.D., and Oberly L.W. The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase. Cancer Res. 60 (2000) 3927-3939
32. Cricco G., Martin G., Lombarda F., Cocca C., Bergoc R., and Rivera E. Human pancreatic carcinoma cell line Panc-I and the role of histamine in growth regulation. Inflammation Res. 49 (2000) 68-69
33. Adams W.J., Lawson J.A., and Morris D.L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 35 (1994) 1632-1636
34. Gorman A., McGowan A., and Cotte T.G. Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett. 404 (1997) 27-33
35. Church S.L., Grant J.W., Ridnour L.A., Oberley L.W., Swanson P.E., Meltzer P.S., and Trent J.M. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. USA 90 (1993) 3113-3117
36. Kinnula V.L., and Crapo J.D. Superoxide dismutases in malignant cells and human tumors. Free Radic. Biol. Med. 36 (2004) 718-744
37. Agostinelli E., and Seiler N. Lysosomotropic compounds and spermine enzymatic oxidation products in cancer therapy. Int. J. Oncol. 31 (2007) 473-484